Sign inCreate account

Report workspace tools

NCT03651947COMPLETEDanonymous

A Randomized, Double-blind and Parallel Group Study to Compare the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

Sponsor

Source record

Qilu Pharmaceutical Co., Ltd.

Phase

Source record

Phase I

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

QL1206, Xgeva®

Indication / condition

AI-normalized

Healthy People

Intervention

Source record

QL1206, Xgeva®

Source & freshness

Source record

NCT ID

NCT03651947

Original source

ClinicalTrials.gov

Source last updated

Oct 16, 2019

Ingested at

Jun 04, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03651947

Title

A Randomized, Double-blind and Parallel Group Study to Compare the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

Sponsor

Qilu Pharmaceutical Co., Ltd.

Status

COMPLETED

Phase

Phase I

Condition raw

Healthy People

Condition normalized

Healthy People

Modality raw

small molecule

Modality normalized

monoclonal antibody

Target raw

QL1206, Xgeva®

Target normalized

QL1206, Xgeva®

Interventions

QL1206, Xgeva®

Public preview

Source record

QL1206 is being developed by Qilu Pharmaceutical Co., Ltd. as a biosimilar to Xgeva® (Denosumab), targeting the treatment of conditions related to bone metabolism. The trial aimed to establish pharmacokinetic, safety, and pharmacodynamic similarities between QL1206 and Xgeva® in healthy adults.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-blind and Parallel Group Study to Compare the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03651947

Status

COMPLETED

Phase

Phase I

Sponsor

Qilu Pharmaceutical Co., Ltd.

Executive brief

Investment-Ready Snapshot

QL1206 is being developed by Qilu Pharmaceutical Co., Ltd. as a biosimilar to Xgeva® (Denosumab), targeting the treatment of conditions related to bone metabolism. The trial aimed to establish pharmacokinetic, safety, and pharmacodynamic similarities between QL1206 and Xgeva® in healthy adults.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 16, 2019
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03651947

Indication

Healthy People

Modality

monoclonal antibody

Target

QL1206, Xgeva®

Intervention

QL1206, Xgeva®

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.